Evaluation of the in vitro activity of ceftobiprole against clinical isolates of Staphylococcus aureus
Submitted: 27 July 2016
Accepted: 18 September 2016
Published: 22 December 2016
Accepted: 18 September 2016
Abstract Views: 1019
PDF: 571
HTML: 525
HTML: 525
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Materials and methods: One hundred and forty blood isolates of S. aureus were evaluated, including methicillin-susceptible (MSSA, n=70) and MRSA (n=70) strains. Twenty additional MRSA isolates obtained from different sites (including skin and soft tissues, blood, and lower respiratory tract) and characterized by borderline susceptibility to vancomycin were also studied to assess the ability of ceftobiprole to overcome this worrisome trait. MIC values of ceftobiprole were determined by Etest strips and results were interpreted according to EUCAST guidelines.
Results and conclusions: Study isolates were consistently susceptible to ceftobiprole, with MIC values ranging from 0.125 mg/L to 2 mg/L. Overall, MIC50 and MIC90 were 0.25 mg/L and 0.5 mg/L, respectively. Ceftobiprole showed in vitro activity against all S. aureus isolates, with small differences among groups selected on the basis of resistance to methicillin and/or reduced susceptibility to vancomycin. Thus, ceftobiprole appears a valid choice for treating infections caused by S. aureus, even when susceptibility results are not yet available. Additionally, ceftobiprole may be a valid option in the case of reduced susceptibility to vancomycin.
Mauri, C., Bracco, S., Meroni, E., Oggioni, D., Principe, L., Pini, B., & Luzzaro, F. (2016). Evaluation of the in vitro activity of ceftobiprole against clinical isolates of Staphylococcus aureus. Microbiologia Medica, 31(4). https://doi.org/10.4081/mm.2016.6205
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.